34144 Federal Register / Vol. 83, No. 139 / Thursday, July 19, 2018 / Notices 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

International Research and Training Program 

Support Services (1158). 

Date: August 9, 2018. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Susan O. McGuire, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Blvd., 

Room 4245, Rockville, MD 20852, 301–827– 

5817, mcguireso@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: July 13, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–15358 Filed 7–18–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Newborn Screening 

Translational Research Network (NBSTRN) 

August 13, 2018. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6710 B 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Sathasiva B. Kandasamy, 

Ph.D., Scientific Review Administrator, 

Division of Scientific Review, National 

Institute of Child Health and Human 

Development, 6710B Rockledge Drive, 

Bethesda, MD 20892, (301) 435–6680, 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: July 13, 2018. 

Ronald J. Livingston, Jr., 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–15357 Filed 7–18–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Planning Grant to Develop 

Phase III Clinical Trials for LBD. 

Date: August 6, 2018. 

Time: 3:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Ana Olariu, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3208, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, ana.olariu@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: July 13, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–15359 Filed 7–18–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Substance Abuse 

Prevention; Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given for the meeting of 

the Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention 

National Advisory Council (CSAP NAC) 

on August 1, 2018. 

The Council was established to advise 

the Secretary, Department of Health and 

Human Services (HHS); the Assistant 

Secretary for Mental Health and 

Substance Use, SAMHSA; and Director, 

CSAP concerning matters relating to the 

activities carried out by and through the 

Center and the policies respecting such 

activities. 

The meeting will be open to the 

public and will include the discussion 

of the substance use prevention 

workforce and opioid use prevention. 

The meeting will also include updates 

on CSAP program developments. 

The meeting will be held in Rockville, 

Maryland. Attendance by the public 

will be limited to the space available. 

Interested persons may present data, 

information, or views, orally or in 

writing, on issues pending before the 

Council. Written submissions should be 

forwarded to the contact person on or 

before one week prior to the meeting. 

Oral presentations from the public will 

be scheduled at the conclusion of the 

meeting. Individuals interested in 

making oral presentations should notify 

the contact on or before one week prior 

to the meeting. Five minutes maximum 

will be allotted for each presentation. 

To attend onsite, submit written or 

brief oral comments, or request special 

accommodations for persons with 

disabilities, please register at the 

SAMHSA Committees’ website, http://

nac.samhsa.gov/Registration/ 


sradovich on DSK3GMQ082PROD with NOTICES